Rituximab is effective in the management of refractory autoimmune cytopenias occurring after allogeneic stem cell transplantation.

Raj, K; Narayanan, S; Augustson, B; Ho, A; Mehta, P; Duncan, N; Tauro, S; Mahendra, P; Craddock, C; Mufti, G

Raj, K; Narayanan, S; Augustson, B; Ho, A; Mehta, P; Duncan, N; Tauro, S; Mahendra, P; Craddock, C; Mufti, G.

Affiliation

Raj K; Department of Haematology, Guy's, King's and St Thomas' School of Medicine, London, UK.

Bone Marrow Transplant ; 35(3): 299-301, 2005 Feb.

Article in En | MEDLINE | ID: mdl-15568036

Subject(s)

Anemia, Hemolytic, Autoimmune/drug therapy; Antibodies, Monoclonal/administration & dosage; Hematopoietic Stem Cell Transplantation/adverse effects; Purpura, Thrombocytopenic, Idiopathic/drug therapy; Salvage Therapy/methods; Adult; Anemia, Hemolytic, Autoimmune/etiology; Antibodies, Monoclonal, Murine-Derived; Disease Management; Female; Hematologic Neoplasms/complications; Hematologic Neoplasms/therapy; Humans; Male; Purpura, Thrombocytopenic, Idiopathic/etiology; Rituximab; Transplantation Conditioning/adverse effects; Transplantation, Homologous; Treatment Outcome

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Salvage Therapy / Purpura, Thrombocytopenic, Idiopathic / Hematopoietic Stem Cell Transplantation / Anemia, Hemolytic, Autoimmune / Antibodies, Monoclonal Type of study: Etiology_studies Limits: Adult / Female / Humans / Male Language: En Journal: Bone Marrow Transplant Journal subject: TRANSPLANTE Year: 2005 Type: Article Affiliation country: United kingdom

Search on Google

XML

PubMed Links